Amicus Therapeutics (FOLD) Shares are Down -0.86%

Amicus Therapeutics (FOLD) has risen sharply, recording gains of 14.52% in the past 4 weeks. However, the stock has corrected -0.86% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 13.35% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 7.5% and the 50-Day Moving Average is 11.88%. Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Friday. Though the stock opened at $6.66, the bulls momentum made the stock top out at $6.95 level for the day. The stock recorded a low of $6.61 and closed the trading day at $6.94, in the green by 3.43%. The total traded volume for the day was 1,315,397. The stock had closed at $6.71 in the previous days trading.


The company Insiders own 8.3% of Amicus Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.29% . During last six month period, the net percent change held by insiders has seen a change of -8.29%. Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Bank of America announces the price target of $10 per share. The rating by the firm was issued on May 18, 2016.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.